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 Abstract.  Chagas disease affects 8–11 million people throughout the Americas. Early detection is crucial for timely 
treatment and to prevent non-vectorial transmission. Recombinant antigen-based rapid tests had high sensitivity and 
specificity in laboratory evaluations, but no Peruvian specimens were included in previous studies. We evaluated Stat-Pak 
and Trypanosoma Detect rapid tests in specimens from Bolivia and Peru. Specimens positive by three conventional assays 
were confirmed positives; specimens negative by two or more assays were confirmed negatives. In Bolivian specimens, 
Stat-Pak and Trypanosoma Detect tests were 87.5% and 90.7% sensitive, respectively; both showed 100% specificity. 
Sensitivity in Peruvian specimens was much lower: 26.6–33.0% (Stat-Pak) and 54.3–55.2% (Trypanosoma Detect); both 
had specificities > 98%. Even in Bolivian specimens, these sensitivities are inadequate for stand-alone screening. The low 
sensitivity in Peru may be related to parasite strain differences. Chagas disease rapid tests should be field tested in each 
geographic site before widespread implementation for screening. 
 INTRODUCTION 
 Chagas disease, caused by the parasite  Trypanosoma 
cruzi , affects an estimated 8–11 million people throughout 
the Americas, and > 100 million people live in areas where 
they are at risk of becoming infected. 1–3 Of those infected, 
as many as 30% develop debilitating—and potentially life-
 threatening—cardiac and/or gastrointestinal disease. 4 People 
become infected when the  T. cruzi –containing feces of the 
blood- sucking triatomine vector contaminate the bite wound 
or mucous membranes. Non-vectorial transmission may occur 
through blood transfusion, organ transplantation, laboratory 
accident, or congenitally. Without successful treatment, infec-
tion is life long. Therapy with currently available antitrypano-
somal drugs is associated with reversion to negative serology 
in 50–60% of treated children 5,6 and may decrease the like-
lihood of clinical progression of Chagas cardiomyopathy in 
adults. 7 Early detection is crucial for timely treatment and to 
prevent non- vectorial transmission. 
 Conventional serologic tests, including the indirect hemag-
glutination assay (IHA), enzyme-linked immunosorbent assay 
(ELISA), and immunofluorescent antibody test (IFA), are 
commonly used to diagnose chronic Chagas disease. Because 
no single test has optimal sensitivity and specificity, the World 
Health Organization recommends the use in parallel of at 
least two distinct serologic assays to confirm  T. cruzi infec-
tion. 1 Epimastigote lysate-based ELISAs tend to have the 
highest sensitivity but have substantial rates of cross-reaction 
with other infections such as leishmaniasis. 8,9 Furthermore, 
conventional assays require specialized laboratory equipment 
and trained laboratory personnel, and testing may require 
several days. Rapid tests based on recombinant antigens have 
been developed in an effort to improve the specificity of 
Chagas testing and to offer a simple diagnostic technique that 
provides rapid results. One commercially available rapid test 
based on several recombinant antigens, the Stat-Pak (Chembio 
Diagnostic Systems, Medford, NY), showed high sensitivity 
and specificity in laboratory testing of specimens from several 
endemic countries, including Bolivia. 10,11 However, no speci-
mens from Peru were included in the studies published to date. 
At the time we undertook this study, no studies on the perfor-
mance of other rapid tests and no field evaluation of Stat-Pak 
had been published. To assess the utility of these tests for use 
in field studies, we evaluated the performance of two Chagas 
disease rapid tests in serum specimens from Peru and Bolivia. 
 MATERIALS AND METHODS 
 The specimens included in this analysis were collected dur-
ing two epidemiologic studies of Chagas disease. The Bolivian 
specimens were tested in the study hospital laboratory by a 
technician used by the research project following the manufac-
turer’s instructions. Because the performance of the rapid tests 
in Peru was entirely unknown, the Peru specimen evaluation 
followed a stringently timed protocol, including readings by 
two independent observers, and was conducted in the Parasitic 
Diseases Serology Laboratory at the Centers for Disease 
Control and Prevention (CDC), Atlanta, Georgia. Both study 
protocols were approved by the Institutional Review Boards 
of the CDC, Johns Hopkins University Bloomberg School 
of Public Health, and Asociación Benéfica Proyectos en 
Informática, Salud, Medicina y Agricultura (PRISMA), Lima, 
Peru. Additional ethical approvals were obtained from the 
Hospital Universitario Japonés, Santa Cruz, Bolivia, for the 
study in Bolivia and the Instituto Nacional de Salud, Lima, 
Peru, for the Peru study. 
 Source and evaluation of Bolivian specimens.  The Bolivian 
specimens were collected during recruitment for a study 
of congenital Chagas disease transmission in the Hospital 
Universitario Japonés, Santa Cruz, Bolivia, conducted from 
November 2006 to June 2007. Women presenting in labor to 
the obstetrical service of the hospital were asked to partic-
ipate in the first step of the study, the aim of which was to 
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identify women with  T. cruzi infection at risk of transmission 
to their infants. After informed consent, a 5-mL blood speci-
men was collected from each woman, centrifuged in the hospi-
tal laboratory, and separated into clot and several aliquots of 
serum. The study laboratory technician used one fresh serum 
aliquot to perform the Stat-Pak and Trypanosoma Detect 
(InBios International, Seattle, WA) rapid tests in the hospi-
tal laboratory within a few hours of collection, following the 
manufacturer’s instructions. The rapid tests were used before 
their expiration dates. The Stat-Pak tests were donated by 
the Bolivian National Chagas Disease Control program and 
were used with consecutive specimens until the supply ran 
out; therefore, Stat-Pak testing was available for a subset of 
specimens only. The Trypanosoma Detect, which was not com-
mercially available, was a prototype (ITC-8.2) provided by the 
manufacturer. 
 One aliquot of each serum specimen was frozen without 
additives and shipped from Bolivia to the Infectious Disease 
Laboratory at the Universidad Peruana Cayetano Heredia in 
Lima, Peru, where an in-house IFA following standard methods 12 
and two commercially available ELISAs (Chagatek ELISA; 
bioMérieux, Marcy l’Etoile, France [based on epimastigote 
lysate antigen] and Chagatest Recombinante ELISA [recom-
binant proteins]; Wiener Laboratories, Rosario, Argentina) 
were performed on all specimens. Following the manufacturer’s 
instructions for the Chagatek plates, the cut-off was set at 0.100 
optical density units (OD) above the mean absorbance of the 
two negative control specimens included on each plate. For the 
Wiener plates, the cut-off was set at 0.300 OD units above the 
mean absorbance of three negative control specimens; speci-
mens with OD values within the range of the cut-off ±10% 
were considered inconclusive and were re-run. If the OD still 
fell in this range, the final result was considered inconclusive. 
Specimens positive or negative by all three conventional sero-
logic tests were considered to have confirmed results. Specimens 
with discordant or inconclusive results were excluded. 
 Source and evaluation of Peruvian specimens.  The Peruvian 
field site comprised two districts on the outskirts of the city of 
Arequipa where recent vector-borne  T. cruzi transmission had 
been documented. 13–15 Household-level insecticide spray cam-
paigns were carried out by the Ministry of Health in late 2004; 
a serosurvey for Chagas disease was conducted in November–
December 2005. 15 Most participants were recruited in the 
public schools serving the two districts. In addition, the entire 
population of one hillside shantytown was invited to enroll in 
a community-based study. 13 School age children living in the 
shantytown were recruited either in schools or in the commu-
nity. A 5-mL blood specimen (3 mL for children < 5 years of 
age) was collected from each participant, separated into serum 
and cells, aliquoted into cryovials, and frozen without additives 
in the laboratory of the Universidad Nacional de San Agustín 
in Arequipa. Specimens were shipped on dry ice to Lima, Peru, 
for further processing. 
 All Peruvian specimens were tested by the same  T. cruzi epi-
mastigote lysate-based ELISA kit (Chagatek), as for Bolivian 
samples. Frozen aliquots of all ELISA-positive specimens plus 
a 10% random sample of ELISA-negative specimens were 
shipped on dry ice to CDC in Atlanta, and tested by an  in-house 
IFA using standard methods; a titer of 1:32 was considered 
the threshold for a positive result. 12 All specimens positive by 
ELISA or IFA, plus 20% of the negative specimens tested at 
CDC, were frozen and shipped on dry ice to the  laboratory 
of one of the authors (LVK), where they were tested by the 
radioimmune precipitation assay (RIPA). The RIPA is often 
used in the United States to confirm positive results obtained 
in other tests and to resolve the status of specimens with dis-
cordant conventional tests. 16,17 Specimens tested by all three 
assays (at least two assays for ELISA-negative specimens) 
were eligible for inclusion in this analysis. Specimens posi-
tive by all three assays (ELISA, IFA, and RIPA) were consid-
ered confirmed positive. Not all specimens negative by ELISA 
and IFA were tested by RIPA, because of the high cost of this 
assay; specimens were considered confirmed negative if they 
had negative results in the two (ELISA and IFA) or three 
assays (ELISA, IFA, and RIPA) used. 
 Confirmed positive and negative specimens were tested by 
the Stat-Pak and Trypanosoma Detect rapid tests in the CDC 
laboratory. For both tests, the manufacturer’s instructions were 
rigorously followed. Each test was read at 15 minutes based on 
a laboratory timer by two independent observers blinded to 
each other’s reading. The presence of a weak or strong line 
in the reaction zone was recorded as positive; its absence 
was recorded as negative. Readers also recorded comments, 
such as “weak positive,” “very weak positive,” “very faint,” 
or “unreadable.” For sensitivity/specificity analysis, interpre-
tations of “positive,” “weak positive,” “very weak positive,” 
and “very faint” were all considered positive. Specimens with 
“unreadable” rapid test results excluded from analysis. 
 Data analysis.  Sensitivities and specificities with 95% con-
fidence intervals (CIs) and weighted κ coefficients for inter-
observer agreement were calculated using SAS V9.1 and 
SAS Enterprise Guide V4.1 (SAS Institute, Cary, NC). The 
Wilcoxon rank-sum test was used to compare differences for 
Chagatek ELISA absorbance (as measured by OD values 
minus cut-off value) for positive specimens, stratified by coun-
try of origin and rapid test results (true positive versus false 
negative). 
 RESULTS 
 Characteristics of the study populations, specimens, and test-
ing are summarized in  Table 1 . In both cases, the case defini-
tion for confirmed positive specimens required positive results 
on three conventional serologic tests. 
 Bolivian field assessment.  Of 530 specimens from women 
presenting to give birth in the hospital in Santa Cruz, 151 
(28.4%) were confirmed positive and 365 (68.9%) were con-
firmed negative by all three conventional tests (Chagatek 
ELISA, Wiener ELISA, and IFA). Fourteen (2.6%) specimens 
with discordant (nine) or inconclusive (five) serologic results 
were excluded from the analysis. The Trypanosoma Detect was 
positive in 137 of the 151 confirmed positive sera and negative 
in all 365 confirmed negative sera, corresponding to a sensitiv-
ity of 90.7% and specificity of 100% ( Table 2 ). The Stat-Pak 
was positive in 21 of 24 confirmed positive sera and negative 
in all 69 confirmed negative sera tested, yielding a sensitivity 
of 87.5% and specificity of 100%. 
 Six Stat-Pak readings carried the comment “weak posi-
tive” and one “very weak positive,” representing 30% of all 
positive readings; all were considered positive following the 
manufacturer’s instructions, and all were confirmed positive in 
the conventional tests. Two specimens had Stat-Pak–negative 
readings at 15 minutes but “very weak positive” at 25–30 min-
utes; based on the manufacturer’s instructions, these readings 
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were considered negative. One of these specimens was con-
firmed positive and the other negative based on the three con-
ventional tests. Fifteen Trypanosoma Detect readings, or 10% 
of positive readings, were recorded as “weak positive,” three 
of which were also “weak positive” on Stat-Pak. All were posi-
tive on the three conventional serologic tests. 
 Evaluation in Peruvian specimens.  The serosurvey in Peru 
included 2,254 specimens, of which 120 (5.3%) were positive 
by the screening ELISA. Of these, 364 (120 positive and 244 
negative by the screening ELISA) were shipped to CDC for 
confirmatory testing. At CDC, 102 (85.0%) of 120 ELISA-
positive specimens and 5 (2.0%) of 244 ELISA-negative spec-
imens were positive by IFA. Four ELISA-positive specimens 
lacked sufficient remaining volume to perform RIPA. RIPA 
results were therefore available for 98 of the 102 specimens 
positive by ELISA and IFA; 97 (99.0%) were positive, whereas 
1 (1.0%) had an indeterminate RIPA result and was excluded 
from further analysis. Of 240 specimens negative by ELISA 
and IFA, 48 were tested by RIPA; 46 (95.8%) were nega-
tive. One (2.1%) was positive by RIPA, and one (2.1%) had 
an indeterminate result; these specimens also were excluded 
from further analysis. The group of specimens used to eval-
uate rapid test performance therefore consisted of 97 speci-
mens positive by ELISA, IFA, and RIPA and 238 specimens 
negative by ELISA and IFA, 46 of which also were confirmed 
negative by RIPA ( Table 1 ). 
 The observers reading the rapid tests in Peruvian speci-
mens reported many weak and indeterminate readings for 
both tests. Although the tests are intended to be read as “posi-
tive” or “negative,” 100 (59%) of the 169 positive test readings 
from two readers carried notations of “weak positive,” “very 
weak positive,” or “very faint” on one or both rapid tests 
( Figure 1 ). Weighted κ coefficient for interobserver agree-
ment was 0.760 (95% CI: 0.652–0.867) for Stat-Pak, reflect-
ing “substantial” agreement between readers and 0.833 
(95% CI: 0.780–0.885) for Trypanosoma Detect, or “almost per-
fect” agreement between readers. The Stat-Pak showed sensi-
tivities of 26.6% by Observer 1 and 33.0% by Observer 2; the 
specificity by both readers was 99.6% ( Table 3 ). Trypanosoma 
Detect sensitivities were 53.8% and 54.6%; specificities were 
98.7% and 98.3%. 
 TABLE 1 
 Comparison of characteristics of the specimens from Bolivia and Peru included in this analysis 
Source Bolivia Peru
Population sampled Pregnant women All ages, school-aged children over-represented
Mean age in years (range) 24.7 (13–45) 16.2 (2–68)
Female sex 100% 52%
Time frame of collection November 2006–June 2007 November–December 2005
Specimen collected 5 mL blood 5 mL blood*
Rapid tests and location Stat-Pak (HUJ†) Stat-Pak (CDC‡)
 Trypanosoma Detect (HUJ†) Trypanosoma Detect (CDC‡)
Conventional serologic testing and location
Screening test Chagatek epimastigote lysate ELISA (UPCH§) Chagatek epimastigote lysate ELISA (UPCH§)
Confirmatory test 1 IFA (UPCH§) IFA (CDC‡)
Confirmatory test 2 Wiener Chagatest Recombinante ELISA (UPCH§) RIPA (UI¶)
Case definitions   
Confirmed positive specimen Positive on all three tests performed Positive on all three tests performed
Confirmed negative specimen Negative on all three tests performed Negative on all tests performed (two or three)**
Eligible specimens†† 530 358
Specimens included in this analysis 516 335
Confirmed positive 151 97
Confirmed negative 365 238
 * Three millilters of blood for children < 5 years old. 
† Hospital Universitario Japonés, Santa Cruz, Bolivia. 
‡  Centers for Disease Control and Prevention, Atlanta, Georgia. 
§ Universidad Peruana Cayetano Heredia, Lima, Peru. 
¶ University of Iowa, Iowa City, IA. 
** If RIPA was run; specimens with negative results on Chagatek ELISA and IFA were considered confirmed negative, if RIPA was not performed. 
††  Eligible specimens were those tested by three conventional serologic assays (at least two assays for negative specimens from the Peru study). Fourteen Bolivian specimens were excluded (nine 
with discordant and six with inconclusive results). Twenty-three Peruvian specimens were excluded (20 with discordant and 3 with inconclusive results). 
 TABLE 2 
 Performance of two rapid tests in specimens from Santa Cruz, Bolivia* 
Conventional 
serology
Chembio Stat-Pak InBios Trypanosoma Detect
Negative Positive Negative Positive
Negative 69 0 365 0
Positive 3 21 14 137
Sensitivity† 87.5 (67.6–97.3) 90.7 (84.9–94.8)
Specificity† 100 (94.8–100) 100 (99.0–100)
 *  A lysate-based ELISA, a recombinant ELISA, and radioimmune precipitation assay were 
used to determine the final status of the specimens. 
† Sensitivity or specificity expressed as a percentage and 95% CI. 
 FIGURE 1.  The InBios Trypanosoma Detect (left) and Chembio 
Chagas Stat-Pak (right) rapid tests. Note the weak positive results in 
each of the tests. This figure appears in color at  www.ajtmh.org. 
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 ELISA results.  The ELISA absorbance among confirmed 
positive specimens was significantly higher in Bolivian than 
Peruvian specimens (0.842 versus 0.305;  P < 0.0001;  Figure 2 ). 
For Trypanosoma Detect, Bolivian specimens with true-
 positive results had a median absorbance of 0.873 versus 0.203 
for false negatives ( P < 0.0001); in Peruvian specimens, the 
respective values were 0.394 and 0.195 ( P < 0.0001;  Figure 3 ). 
For Stat-Pak, the median for Bolivian specimens with true-
positive results was 0.831 compared with 0.122 for false nega-
tives ( P = 0.08); in Peruvian specimens, the respective values 
were 0.470 and 0.254 ( P < 0.05;  Figure 4 ). 
 DISCUSSION 
 Our evaluation of the Chembio Stat-Pak and InBios 
Trypanosoma Detect rapid tests in specimens from Bolivia and 
Peru showed highly variable sensitivities. In Peruvian speci-
mens, both rapid tests had sensitivities < 60%, making them 
unusable in this setting in their current forms. Although the 
sensitivities in Bolivian specimens were much higher than in 
Peruvian samples, they still fell short of previously published 
values, 10,11,18 missing 10% or more of specimens confirmed pos-
itive by conventional serology. In both locations, the ELISA 
absorbance values were significantly higher among specimens 
with true-positive rapid test results than among those with 
false-negative results, suggesting that the rapid test  detection 
thresholds may be set too high. In Peru, many rapid test read-
ings were noted as “very weak” and therefore difficult to 
interpret. Nevertheless, interobserver agreement was high. 
The specificities determined in specimens from both locations 
were acceptably high. 
 The poor sensitivity of the Stat-Pak test, particularly in the 
Arequipa specimens, contrasts sharply with previously pub-
lished data on its performance. One evaluation of Stat-Pak 
showed sensitivities of 98.5% in 393 Brazilian specimens and 
100% in 352 specimens from Honduras, Argentina, Venezuela, 
and Bolivia. 10 An evaluation of the Stat-Pak in nearly 6,000 
blood bank specimens from Honduras, El Salvador, and 
Nicaragua showed sensitivity of 99.6%. 11 The Stat-Pak was 
found to have a somewhat lower sensitivity of 93.4% in a 
recent field study in Sucre, Bolivia. 18 The authors hypothe-
sized that the lower sensitivity resulted from the use of whole 
blood instead of serum; however, no results using serum from 
the same study subjects were provided to address this issue. 
Another recently published study from southern Bolivia 
reported a 5.9% discordance rate between Stat-Pak and an 
epimastigote lysate-based ELISA (Wiener Chagatest), but no 
details were provided regarding the rate of false-positive and 
false-negative results. 19 
 Our findings suggest that there may be more regional varia-
tion in antibody response to  T. cruzi infection than is usually 
acknowledged. 20 In a study using ELISAs based on each of 
 FIGURE 2.  Distribution and median of Chagatek ELISA absor-
bance (OD minus cut-off value) among confirmed positive samples 
in studies in Bolivia and Peru. Confirmed positive specimens were 
defined as those with positive results on all three conventional sero-
logic tests (Chagatek ELISA, IFA, and either Wiener Recombinant 
ELISA [Bolivia] or RIPA [Peru]). 
 TABLE 3 
 Performance of two rapid tests in specimens from Arequipa, Peru* 
Chembio Stat-Pak InBios Trypanosoma Detect
Observer 1 Observer 2 Observer 1 Observer 2
Negative Positive Negative Positive Negative Positive Negative Positive
Negative 237  1 237  1 235  3 234  4
Positive  69 25  65 32  43 50  44 53
Sensitivity† 26.6 (18.0–36.7) 33.0 (23.8–43.3) 53.8 (43.1–64.2) 54.6 (44.2–64.8)
Specificity† 99.6 (97.7–100) 99.6 (97.7–100) 98.7 (96.4–99.7) 98.3 (95.7–99.5)
 Each test was read by two independent observers. 
*  A lysate-based ELISA, a recombinant ELISA, and radioimmune precipitation assay were used to determine the final status of the specimens. 
†  Sensitivity or specificity expressed as a percentage and 95% CI. 
 FIGURE 3.  Distribution and median of Chagatek ELISA absor-
bance (OD minus cut-off value) of confirmed positive samples with 
true-positive and false-negative results by Trypanosoma Detect rapid 
test in studies in Bolivia and Peru. 
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six recombinant  T. cruzi antigens (including at least three of 
the antigens used in the Stat-Pak) to test sera from Argentina, 
Bolivia, Brazil, Chile, Colombia, El Salvador, Guatemala, 
Honduras, and Venezuela, Umezawa and others 21 found that 
the reactivity of individual antigens varied by geographic 
region. Although a whole epimastigote-lysate-based ELISA 
had a sensitivity of 100%, individual antigens reacted with 
79–100% of seropositive samples from the various countries. 
Another analysis showed consistently lower absorbance val-
ues for some recombinant antigens in specimens from Panama 
compared with Bolivia, Brazil, and Honduras. 22 We found 
much lower epimastigote lysate ELISA absorbance values in 
Peru compared with Bolivia, suggesting a less robust antibody 
response in Peru. Because the populations of Santa Cruz and 
Arequipa are fairly comparable mixes of European and Native 
American descendants, human genetic factors are unlikely 
to explain this major difference in immunologic response. 
We suspect that the variable performance of these two rapid 
tests may be caused by parasite heterogeneity. The species 
 T. cruzi includes several strains with heterogeneous genetic 
and phenotypic characteristics, 23 but the implications for use 
of recombinant antigens for serologic diagnosis are as yet 
undetermined. There are no published evaluations of Chagas 
rapid test performance or of the performance of recombinant 
antigen-based ELISA kits in Peruvian specimens, and our data 
raise questions about the assumption that these two rapid tests 
will perform similarly in the various regions of Latin America 
in which Chagas disease is endemic. 
 This study had a number of limitations. The samples were 
collected in a limited geographic area within each country, and 
our results cannot be generalized to other locations. The epi-
demiologic methods and objectives were different in the two 
studies, and the distributions by age and sex were therefore 
different ( Table 1 ). However, there are no data to suggest that 
the sensitivity of rapid tests should vary greatly between males 
and females or among school-aged children compared with 
pregnant women. Because both populations are prime targets 
for Chagas disease screening in current control programs, it is 
important that any screening test be equally effective for both. 
We were unable to use the same second confirmatory test 
(RIPA) in Bolivian as Peruvian specimens because of resource 
constraints. Nevertheless, we believe that our definition of 
confirmed positive was equally stringent for both sets of speci-
mens. Indeed, the use of three tests may have excluded posi-
tive specimens with lower antibody levels and thereby resulted 
in an overestimate of the true sensitivity of the rapid tests. The 
only methodologic difference that might contribute to a lower 
sensitivity in the Peru specimens was the fact that they had 
been through two freeze-thaw cycles before the rapid tests 
were used, whereas the Bolivian specimens were tested fresh. 
However, RIPA testing of the Peruvian specimens occurred 
after a third freeze-thaw cycle and showed high concordance 
with the screening ELISA. In any case, two freeze-thaw cycles 
should not cause a 50–70% decrease in the sensitivity of a 
robust serologic test. Clearly, further evaluations of rapid test 
performance in a broader range of populations and under a 
variety of conditions are still needed. 
 Rapid tests for Chagas disease have the potential to facil-
itate both prenatal screening and surveys to detect infected 
children who would benefit from drug treatment. To date, the 
challenging logistics of community and hospital-based screen-
ing and follow-up have prevented these efforts from reaching 
large proportions of the population in need. 24 The Stat-Pak and 
Trypanosoma Detect rapid tests are simple to use and require 
no refrigeration, specialized equipment, or highly trained lab-
oratory personnel. The results are available within 15 minutes, 
eliminating the need to return a second time to a community 
or to track down an infected woman after discharge from the 
hospital. The use of recombinant antigens rather than whole 
epimastigote preparations may improve the specificity of 
Chagas testing, particularly in areas where Chagas disease and 
leishmaniasis are co-endemic. These attributes make rapid 
tests very appealing for use in field epidemiology and clini-
cal diagnostics. Stat-Pak has been used for community-based 
screening of children in Bolivia, 25 and its use has been advo-
cated for other settings where conventional serology is not 
readily available. 10,11 
 However, the specific antigens and format used in rapid 
tests may result in varying sensitivity depending on the loca-
tion in which the test is applied; Arequipa seems to be one 
such location for which these rapid tests are not well adapted. 
Furthermore, rapid test sensitivity in Bolivian specimens was 
low for use as the sole screening tool. A child or pregnant 
woman with a false-negative rapid test may not ever be tested 
again, but a false-positive rapid test result will be detected 
when confirmatory serology is run. Thus, higher sensitivity 
would be worth the trade-off of lower specificity that would 
inevitably result from lowering the detection threshold. Until 
consistently high sensitivity can be shown, rapid diagnos-
tic tests should be carefully evaluated in specimens from the 
intended target locations before widespread implementation, 
and screening of new populations should continue to include 
testing by sensitive conventional assays in all specimens. 
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